{
  "id": 7328434,
  "title": "STAT+: GSK touts lung cancer data from two drugs",
  "url": "https://urgent.news/2026/09/14/stat-gsk-touts-lung-cancer-data-from-two-drugs",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T13:34:37.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/09/14/biotech-news-gsk-touts-lung-cancer-data-from-two-drugs/"
  },
  "original_language": "en",
  "account": null,
  "summary": "GSK has announced positive results from the ARROS-1 trial of its drug Jideytro, also known as zidesamtinib, in patients with ROS1-positive non-small cell lung cancer who had not previously received treatment with a tyrosine kinase inhibitor. According to Investing.com, the trial showed that in 94 treatment-naïve patients, zidesamtinib achieved a 94% objective response rate after a median follow-up of 15.2 months, including a 15% complete response rate.\n\nThe trial also found that progression-free survival was 90% at 12 months, and median duration of response and median progression-free survival had not been reached at the time of analysis. Among 10 patients with measurable brain metastases at baseline, all responded to treatment, with 70% achieving complete clearance of detectable brain tumors.\n\nGSK plans to submit a supplemental New Drug Application to the U.S. FDA this year to expand Jideytro's indication to include first-line treatment. The most common treatment-related adverse events were peripheral edema, weight increase, blood creatine phosphokinase increase, dysgeusia, and aspartate aminotransferase increase.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "GSK presents positive trial data for lung cancer drug Jideytro",
        "url": "https://urgent.news/2026/09/14/gsk-presents-positive-trial-data-for-lung-cancer-drug-jideytro",
        "published": "2026-09-14T06:25:54.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}